Compare Ascendis Pharma A/S (ASND) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Kingsoft Cloud Holdings Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Kingsoft Cloud Holdings Limited trades at $10.6 (market cap $3.25B). The key difference: Ascendis Pharma A/S is far larger — about 5.5× Kingsoft Cloud Holdings Limited's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| ASND | KC | |
|---|---|---|
Market Cap | $17.74B | $3.25B |
Sector | Health | Technology |
52-Week High | $277.18 | $18.21 |
52-Week Low | $163.32 | $8.58 |
Enterprise Value | $18.11B | $3.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kingsoft Cloud (KC) trades at $10.91, up 4.2% today, with a bullish technical signal and strong analyst support (70% buy ratings). Recent earnings beats and accelerating revenue growth, driven by AI cloud demand, highlight operational momentum, though profitability remains negative. The stock is near resistance at $11, with RSI indicating potential overbought conditions short-term.
The outlook is cautiously optimistic given AI-driven growth potential and positive sentiment, but risks include persistent losses, high capital expenditure, and competitive pressures. Upside depends on margin improvement from AI investments, making KC a speculative growth play with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
